Press Releases

Tel Aviv, Israel— June 20, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS was featured at the SBHCI Congress, sponsored by the Brazilian Society of Hemodynamics and Interventional Cardiology, which took place in Curitiba, Brazil from June 13-15,… Read More

Study results presented from 46 patients treated over two years with zero complications President of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of CGuard™ EPS Tel Aviv, Israel— June 18, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,… Read More

Tel Aviv, Israel— June 11, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ MicroNet™ covered Embolic Prevention System (EPS) was successfully featured in a live case transmission on June 8th to the 2nd DGA Interventional Congress of the… Read More

Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months Tel Aviv, Israel— May 30, 2018 –  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS),  thrombus management technologies and neurovascular devices, today announced that Professor Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II… Read More

Tel Aviv, Israel— May 16, 2018 –  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ from the Ministry of Health in Ecuador. Both of these devices utilize the… Read More

Tel Aviv, Israel— May 7, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the first quarter ending March 31, 2018. First Quarter 2018 highlights: Achieves revenue of $1.0 million for Q1 2018 versus $569,000 in Q1 2017, an increase… Read More

Tel Aviv – May 1, 2018 – InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Monday, May 7th at 4:30 p.m. Eastern Time to discuss the company’s financial results for the first quarter ended March… Read More

Tel Aviv, Israel— April 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval, and has initiated commercialization of its CGuard™ Embolic Prevention System (EPS) and MGuard Prime™ in Vietnam.  Both of these devices utilize the company’s patented MicroNet™… Read More

 Tel Aviv, Israel— April 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System will be featured at the ICCA Stroke 2018 conference to be held April 20th-21st at the Institute of Psychiatry and Neurology in Warsaw, Poland…. Read More

Tel Aviv, Israel— April 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for the first quarter of 2018. Highlights for the fiscal first quarter of 2018 as compared to the fiscal first quarter of 2017(1): ⦁ Total company… Read More